Literature DB >> 16700826

Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population.

Claire Larramendy-Gozalo1, Jue Quin Yang, Céline Verstuyft, Laurent Bodin, Liliane Dubert, Yong Zhang, Chundi Xu, Lian Fan, Patrice Jaillon, Laurent Becquemont.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16700826     DOI： 10.1111/j.1742-7843.2006.pto_440.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN： 1742-7835            Impact factor:   4.080


× No keyword cloud information.
  10 in total

1.  A pharmacokinetic-pharmacodynamic model for predicting the impact of CYP2C9 and VKORC1 polymorphisms on fluindione and acenocoumarol during induction therapy.

Authors:  Céline Verstuyft; Xavier Delavenne; Alexandra Rousseau; Annie Robert; Michel Tod; Bertrand Diquet; Martine Lebot; Patrice Jaillon; Laurent Becquemont
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

2.  CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.

Authors:  Han-Jing Cen; Wu-Tao Zeng; Xiu-Yu Leng; Min Huang; Xiao Chen; Jia-Li Li; Zhi-Ying Huang; Hui-Chang Bi; Xue-Ding Wang; Yan-Ling He; Fan He; Rui-Na Zhou; Qi-Shan Zheng; Li-Zi Zhao
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

3.  Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione.

Authors:  Karine Lacut; Estelle Ayme-Dietrich; Lenaick Gourhant; Elise Poulhazan; Marion Andro; Laurent Becquemont; Dominique Mottier; Gregoire Le Gal; Celine Verstuyft
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

4.  Amoxicillin/clavulanic acid-warfarin drug interaction: a randomized controlled trial.

Authors:  Qian Zhang; Guy Simoneau; Celine Verstuyft; Ludovic Drouet; Claire Bal dit Sollier; Jean-Claude Alvarez; Nathalie Rizzo-Padoin; Jean Francois Bergmann; Laurent Becquemont; Stéphane Mouly
Journal:  Br J Clin Pharmacol       Date:  2011-02       Impact factor: 4.335

Review 5.  Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.

Authors:  Joseph P Kitzmiller; David K Groen; Mitch A Phelps; Wolfgang Sadee
Journal:  Cleve Clin J Med       Date:  2011-04       Impact factor: 2.321

Review 6.  The pharmacogenetics of the response to warfarin in Chinese.

Authors:  May P S Lam; Bernard M Y Cheung
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

7.  Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement.

Authors:  Danxin Wang; Huizi Chen; Kathryn M Momary; Larisa H Cavallari; Julie A Johnson; Wolfgang Sadée
Journal:  Blood       Date:  2008-06-03       Impact factor: 22.113

Review 8.  Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice.

Authors:  Laurent Becquemont
Journal:  Eur J Clin Pharmacol       Date:  2008-08-30       Impact factor: 2.953

9.  Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population.

Authors:  Xiaojuan Yan; Feng Yang; Hanyun Zhou; Hongshen Zhang; Jianfei Liu; Kezhong Ma; Yi Li; Jun Zhu; Jianqiang Ding
Journal:  Med Sci Monit       Date:  2015-11-19

10.  Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.

Authors:  Jiao Li; Wenlong Yang; Zhonghui Xie; Kun Yu; Yuhua Chen; Kaijun Cui
Journal:  BMC Cardiovasc Disord       Date:  2018-05-18       Impact factor: 2.298
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.